87 Prevention of rheumatoid arthritis 13 Bemis EA, Demoruelle MK, Seifert JA, Polinski KJ, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, ODell JR, Keating RM, Deane KD, Holers VM, Norris JM. 2021; Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Ann Rheum Dis. 80(2):154–61. 14 Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, de Gast T, Habibuw MR, Vandenbroucke JP, Dijkmans BA. 2004; Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 50(8):2423–7. 15 Rantapää-Dahlqvist S, de Jong B a W, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. 2003; Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48(10):2741–9. 16 Burgers L, van Steenbergen HW, ten Brinck RM, Huizinga T, van der Helm-van Mil AHM. 2017; Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis. Ann Rheum Dis. 76:1751–4. 17 Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S. 2010; Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 62(2):383–91. 18 Hunt L, Hensor EM, Nam J, Burska AN, Parmar R, Emery P, Ponchel F. 2016; T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals. Ann Rheum Dis. 75(10):1884–9. 19 Klarenbeek P, de Hair M, Doorenspleet M, van Schaik B, Esveldt R, van de Sande M, Cantaert T, Gerlag D, Baeten D, van Kampen A, Baas F, Tak P, de Vries N. 2012; Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis. 71(6):1088–93. 20 Thomas R, McIlraith M, Davis LS, Lipsky PE. 1992; Rheumatoid synovium is enriched in CD45RBdim mature memory T cells that are potent helpers for B cell differentiation. Arthritis Rheum. 35(12):1455–65. 21 Kinslow JD, Blum LK, Deane KD, Demoruelle MK, Okamoto Y, Parish MC, Kongpachith S, Lahey LJ, Norris JM, Robinson WH, Holers VM. 2016; Elevated IgA Plasmablast Levels in Subjects at Risk of Developing Rheumatoid Arthritis. Arthritis Rheumatol. 68(10):2372–83. 22 Verheul MK, Bohringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, Holers VM, Edison JD, Deane KD, Janssen KMJ, Westra J, Brink M, Rantapaa-Dahlqvist S, Huizinga TWJ, van der Helm-van Mil AHM, van der Woude D, Toes REM, Trouw LA. 2018; Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals. Arthritis Rheumatol. 70(11):1721–31. 23 Volkov M, Kampstra ASB, van Schie KA, Kawakami A, Tamai M, Kawashiri S, Maeda T, Huizinga TWJ, Toes REM, van der Woude D. 2021; Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications. Arthritis Res Ther. 23(1):298. 24 Huizinga TW, Landewé RB. 2005; Early aggressive therapy in rheumatoid arthritis: a “window of opportunity”? Nat Clin Pr Rheumatol. 1(1):2–3. 25 Neovius M, Simard JF, Klareskog L, Askling J, Group AS. 2011; Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis. 70(8):1407–14. 4
RkJQdWJsaXNoZXIy MTk4NDMw